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A new Zn(II)-based potential chemotherapeutic agent was synthesized from the ligand 2-
quinolinecarboxaldehyde selenosemicarbazone (Hqasesc). Single crystal X-ray diﬀraction analysis
showed that the Zn(II) complex consists of a cation [Zn(Hqasesc)2]
2+, two perchlorate anions and one
ethanol solvent molecule. The interaction of calf thymus (CT) DNA and human serum albumin (HSA) with
the Zn(II) complex was explored using absorption and emission spectral methods, and also has been
supported by molecular docking studies. The complex has more aﬃnity to minor DNA groove than
major, with no signiﬁcant intercalation. The HSA interaction studies of the complex revealed the
quenching of the intrinsic ﬂuorescence of the HSA through a static quenching mechanism. The
antitumor activity of the ligand and the complex against pancreatic adenocarcinoma cell line (AsPC-1)
and acute monocytic leukemia (THP-1) cells was evaluated. Both compounds are strong concentration-
dependent apoptosis inducers in THP-1 cells. While Hqasesc in AsPC-1 cells induces apoptosis only at
the highest concentration, treatment with the Zn complex shows a concentration-dependent apoptotic
response, where the treated cells are arrested in the G1-to-S phase accompanied with extensive
activation of caspase-8 and -9. These results indicate that the ligand and Zn(II) complex display cell
phenotype speciﬁc activity.Introduction
Thiosemicarbazones are condensation products of thio-
semicarbazide and carbonyl compounds, which have been
extensively studied as NS bidentate ligands in coordination
chemistry. They possess imine nitrogen and sulfur donor atoms
from the thiosemicarbazide moiety.1,2 The coordinatione, Nemanjina 6, Belgrade, Serbia
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hemistry 2015capacity of this class of ligands may be extended if there is
a donor atom(s) from the carbonyl compound in a position(s)
suitable to form a chelate ring(s). This class of compounds is
well known to possess a wide range of pharmacological prop-
erties.3 Studies from the 1960s indicated that the mechanism of
action of thiosemicarbazones involves the inhibition of DNA
synthesis.4When it was proven that tumor cells lose their abilityiLaboratoire d’Innovation The´rapeutique, UMR 7200, Faculte´ de Pharmacie,
Universite´ de Strasbourg, 67401 Illkirch, France. E-mail: cdmuller@unistra.fr
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† Electronic supplementary information (ESI) available: FT-IR (Fig. S1) and
NMR (Fig. S2–S9) spectra; cyclic voltammograms (Fig. S10); pH dependent
UV-Vis spectra (Fig. S11 and S12); packing diagrams (Fig. S13 and S14);
sigmoidal dose–response curves (Fig. S15); Stern–Volmer plot (Fig. S16);
modied Stern–Volmer plot (Fig. S17); the plot of ln Ka vs. 1/T (Fig. S18);
double-log plot (Fig. S19); uorescence spectral overlap (Fig. S20);
conformations of the complex in the DNA duplex (Fig. S21); the location of
the HSA–Zn complex binding site (Fig. S22); numbering of atoms (Scheme
S1); hydrogen bonding geometry (Table S1); interactions of HSA binding site
(Table S2). CCDC 1413656 and 1413657. For ESI and crystallographic data in
CIF or other electronic format see DOI: 10.1039/c5ra19849f
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View Article Onlineto convert ribonucleotides to deoxyribonucleotides aer treat-
ment with N-heteroaromatic thiosemicarbazone obtained from
2-formylpyridine, ribonucleotide reductase (RR) was marked as
the main target for NNS chelating thiosemicarbazones. Chela-
tion of iron from the RR active site was proposed to be the
reason for enzyme inactivation.4 Recent ndings indicate other
mechanisms of thiosemicarbazone action: reactive oxygen
species (ROS) generation, DNA binding, topoisomerase II inhi-
bition, mitochondria disruption, inhibition of protein synthesis
and multidrug resistance protein inhibition.4–6
Despite the fact that various thiosemicarbazones have been
developed and even patented as pharmaceuticals,7 the synthesis
and biological activity investigation of this type of compounds is
still a topic of interest. Some recent studies resulted in new
thiosemicarbazone molecules, which are more active than
standard chemotherapeutics.8–13 One strategy for the improve-
ment of biological activity of thiosemicarbazones is the
synthesis of their metal complexes. Coordination of thio-
semicarbazones to metals enhances their lipophilicity by ori-
enting the lipophilic and aromatic parts outwards from the
complex molecules toward the solvent.6 Metal complexes may
be a vehicle for the activation of thiosemicarbazones by
increasing their ability to diﬀuse through the semipermeable
membrane of cells, and complexes oen show less side eﬀects
and diﬀerent bioactivities in comparison to metal-free ligands.3
Selenosemicarbazones are selenium analogues of thio-
semicarbazones and their biological activity has been studied in
a lesser extent, probably because selenium was considered as
a toxic element for humans up to the late 1950s.14 Another
reason might be the instability of this type of compounds as is
apparent from the precipitation of elemental selenium during
the complexation of selenosemicarbazones, modication of
ligands with the evolution of hydrogen selenide, or oxidation
with the formation of diselenide bridges.14 However, some of
synthesized selenosemicarbazones and their complexes showed
good biological activity.15–18 A few comparative studies indicated
that selenosemicarbazones showed similar or even better bio-
logical activities than the corresponding thiosemicarbazones
and their complexes.19–24 We previously synthesized and char-
acterized Zn(II) complexes with N-heteroaromatic selenosemi-
carbazones of 2,6-diacetylpyridine, 2-formylpyridine and
quinoline-2-carboxaldehyde (H2dapsesc, Hfpsesec and Hqa-
sesc, respectively).25–27 In the corresponding complexes the
ligands were coordinated via Naromatic, Nimin, and Se atoms. The
Zn complexes with pyridine derivatives were the subject of
antitumor investigations,27–31 while the complex with a quino-
line derivative was unsuitable due to low solubility. The
complex with H2dapsesc showed a strong dose-dependent
cytotoxic activity, with an IC50 value in the range 13–60 mM on
six human carcinoma cell lines, as determined by a colorimetric
assay aer 24 h incubation.30 On human breast cancer (MDA-
361) and human colon cancer (LS174) cell lines, the IC50
values for this complex were of the same order of magnitude as
IC50 values of cisplatin (CDDP). The Zn complex with a for-
mylpyridine derivative showed a strong cytotoxic eﬀect on the
ve treated human cancer cell lines, in the range of the activity
of CDDP, as determined by a colorimetric assay aer 48 and 7295192 | RSC Adv., 2015, 5, 95191–95211h of incubation.27 It is worth mentioning that this complex had
a low toxicity on normal endothelial cells (EA.hy926), lower in
comparison to the activity on treated cancer cell lines, and even
lower than the activity of CDDP on EA.hy926 cells.
In order to continue our investigation on the antitumor
activity of selenosemicarbazone complexes with biometals we
have synthesized a new Zn complex with the Hqasesc ligand and
evaluated ligand and complex activities on a diﬀerent cancer
cell model than used in our previous studies. While organizing
current research, our guiding idea was to test whether these
compounds can display full-scale anticancer activity. Extensive
research of cancer biology and behavior has revealed that the
same cells, which mediate tumor growth, are also responsible
for resistance to treatment and tumor relapse, and these have
been referred as Cancer Stem Cells (CSCs).32 An important
feature of CSCs is their extensive genomic heterogeneity, which
results in persistent cancer sub-clones with a unique genomic
and epigenomic prole, and each of these sub-clones is prob-
ably endowed with a diﬀerent drug-resistant phenotype.
Furthermore, it was shown that another characteristic of CSCs
is the reversible transition between epithelial andmesenchymal
states in carcinoma. The epithelial–mesenchymal transition
(EMT) is a physiological process that occurs during embryonic
development, which is dened by biochemical changes in
epithelial cells that lead to the acquisition of mesenchymal
properties, including loss of cell adhesion and increased
migratory capacity.33 In cancer, the EMT generates cells with
apparent CSC features and has been associated with more
aggressive tumors.34 Therefore, evidence from experimental
models and clinical studies strongly indicate that the major
goal of the current drug development should be to create an
eﬃcient strategic drug with ability to induce apoptotic death in
all tumor cells including CSCs, as a way to achieve a cancer cure.
For that reason, in the present work we have explored the
activity of the Hqasesc ligand and its Zn complex against
pancreatic adenocarcinoma cell line (AsPC-1), which possesses
characteristics of epithelial–mesenchymal transition (EMT)-
type cells, bearing resistance to three conventional chemo-
therapeutic agents (gemcitabine, 5-uorouracil, and CDDP).35,36
Antitumor activity of the compounds was also evaluated on non-
CSC acute monocytic leukemia (THP-1) cells. Owing to the
noted characteristics, the chosen cell lines represent excellent in
vitro models for the investigation of the Hqasesc ligand and its
Zn complex against the heterogeneity and plasticity of cancer
cells.Results and discussion
The Zn(II)-complex with the ligand Hqasesc was prepared by
a template reaction starting from zinc(II) perchlorate hexahy-
drate, 2-quinolinecarboxaldehyde and selenosemicarbazide
(mole ratio 1 : 2 : 2, respectively). The complex is soluble in
MeOH, EtOH, MeCN, DMF and DMSO at room temperature.
Molar conductivity measurements showed that the complex is
a 1 : 2 electrolyte. Based on these results, as well as results of
elemental analysis, spectroscopic and X-ray diﬀraction studyThis journal is © The Royal Society of Chemistry 2015
Scheme 1 Proteolytic equilibria of Hqasesc in aqueous media. HA, as
neutral form of Hqasesc, is represented in one tautomeric form, while
all tautomers coexist in solution.
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View Article Online(vide infra), the formula of the complex can be written as
[Zn(Hqasesc)2](ClO4)2$EtOH (1).
IR and NMR spectroscopy
The experimental IR spectrum of 1 (Fig. S1a, ESI†) was inter-
preted in terms of a calculated one (Fig. S1b, ESI†) at the B97D/
TZVP level of theory (see Experimental section for details) and
with comparison to the spectrum of themetal-free ligand. In the
IR spectrum of Hqasesc there are sharp medium intensity
bands in the region 3340–3080 cm1 which are assigned to the
n(NH2) and n(NH) stretching vibrations.26 The lack of a large
systematic shi of these bands in the IR spectrum of 1 indicates
that there is no interaction between the terminal nitrogen atom
and zinc ion. As had been previously observed in other sele-
nosemicarbazone complexes,25–28 in the IR spectrum of 1 there
is a systematic shi of the n(C]N) band to a higher frequency in
comparison to that in the corresponding ligand (1607 cm1 in
Hqasesc; 1617 cm1 in 1). Also, in the spectrum of 1 a sharp and
strong band at 1100 cm1 originating from the perchlorate
ion can be observed.
1D (1H and 13C) and 2D (COSY, NOESY, 1H-13C HSQC and
1H-13C HMBC) spectra of 1 were recorded in DMSO-d6 and are
shown in Fig. S2–S7 (ESI†) together with the atom numbering
scheme (Scheme S1, ESI†). NMR spectral data for Hqasesc are in
full agreement with previously published data.26 In all the 1D
spectra of 1 there is only one set of signals, indicating the
presence of just one form of the complex in solution. Based on
the presence of the H–N3 signal at 12.56 ppm in the 1H NMR
spectrum of 1, the ligand is coordinated to Zn(II) in the neutral
form. It has already been documented that NMR signal shis
for Zn-thio(seleno)semicarbazone complexes in comparison to
corresponding signals for free ligands are less pronounced than
for other chalcogensemicarbazone d-metal complexes.25,27,37,38
Coordination of the Zn(II) ion to Hqasesc gives rise to downeld
shis of all protons in the 1H NMR spectrum (Fig. S8a, ESI†),
together with shis of almost all signals in the 13C NMR spec-
trum (Fig. S8b, ESI†). The quinoline nitrogen atom coordina-
tion is corroborated by a signicant downeld shi of the signal
of C4–H in the proton NMR and the signal of C4 in the carbon
NMR spectrum, as well as the upeld shi of signals of C8a and
C2 in the carbon NMR spectrum of 1. The downeld shi of the
C9 signal in the 13C NMR spectrum indicates imine nitrogen
coordination, while due to selenium atom coordination the
signals of N4Ha and N4Hb are signicantly shied downeld. A
shi of the signal of the selenone carbon atom (C]Se) in the
spectrum of 1 is similar to those reported for analogous Zn-
chalcogensemicarbazone complexes.25,27,37 The complex 1 was
quite stable, as can be seen from the proton spectra of a freshly
prepared sample and a sample aer 24 h (Fig. S9, ESI†).
Cyclic voltammetry
The redox behavior of Hqasesc and 1 have been investigated by
cyclic voltammetry (Fig. S10, ESI†) in a potential range from +1.2
to 2.0 V relative to a Ag/AgCl reference electrode. Repeated
scans, as well as diﬀerent scan rates, showed that dissociation
of the ligand does not take place in 1. In the cyclicThis journal is © The Royal Society of Chemistry 2015voltammogram of the ligand, two cathodic peaks at 1.38
and 1.93 V vs. Ag/AgCl were observed. The rst peak can be
attributed to imine bond reduction since a similar value (1.33
V) was assigned to a pyridinium analogue of Hqasesc.39 It is
reasonable to assume that the second peak resulted from sele-
noamide reduction. Namely, similar values for benzil bis(thio-
semicarbazone) (1.440 and 1.746 V vs. Ag/AgCl) were
assigned to imine and thioamide reduction, respectively.40 In
the reverse scan process, no anodic peaks were observed, indi-
cating that these electrochemical processes were coupled with
a chemical reaction (EC mechanism).41 In the cyclic voltam-
mogram of 1 the corresponding cathodic peaks are shied to
positive positions (1.35 and 1.84 V vs. Ag/AgCl) due to the
metal–ligand orbital interactions, as was noticed for the Zn
complex with 4-phenyl-1-[(4-methoxyphenyl)methylene]-thio-
semicarbazide.42 In the range from 0 to 1.3 V additional
reduction peaks are observed in the cyclic voltammogram of 1,
as in the case of the Zn–benzil bis(thiosemicarbazone)
complex.40 The number of reduction peaks is equal for Hqasesc
and 1 which indicates that the complex is stable – the Zn(II) ion
is “hidden” for reduction in the chelate structure. On the other
hand, the number of oxidation peaks in the cyclic voltammo-
grams of Hqasesc and 1 is diﬀerent (Hqasesc: 0.32 and 0.02 V
vs. Ag/AgCl; 1: 0.30, 0.04 and 0.52 V vs. Ag/AgCl). The addi-
tional oxidation peak can be assigned to Zn(II) ion oxidation,
which is proven by addition of Zn(ClO4)2$6H2O to a solution of 1
(Fig. S10, ESI†).Determination of acidity constants of Hqasesc
The acidity constants of the ligand were determined using
spectrophotometric titration at T ¼ 298  1 K. Within the
studied pH range (1.65–11.91) Hqasesc acts as a sparingly
soluble ampholyte (Scheme 1).
UV-Vis spectra of Hqasesc in pH ranges 1.65–5.17 and 5.17–
11.91 are shown in Fig. S11a and S12a (ESI†). The existence of
two pH regions with clearly visible isosbestic points indicates
that the two pKa values are well separated (DpKa > 3). The
existence of isosbestic points proves that the only process in
solution within both pH ranges is the proteolytic equilibrium
shown in Scheme 1. This makes the spectrophotometric
method valid for pKa value determination. Acidity constant (Ka1
and Ka2) values were calculated according to transformed forms
of the classical spectrophotometric equation,43 which gives
a linear dependence (for details see Experimental part). A value
of Ka1 was obtained as the slope from the corresponding linear
dependencies at four wavelengths (287, 327, 341, 390 nm), whileRSC Adv., 2015, 5, 95191–95211 | 95193
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View Article OnlineKa2 was obtained as the slope from the corresponding linear
dependencies at three wavelengths (266, 330, 365 nm). Exam-
ples are shown in Fig. S11b and S12b (ESI†). The obtained pKa1
and pKa2 values are given in Table 1 and the corresponding
distribution diagram in Fig. 1. It should be noted that all
determined constants represent macro ionization constants. As
shown in Scheme 1, Ka1 represents the dissociation of the
protonated quinoline nitrogen, while Ka2 accounts for diﬀerent
contributions of the selenone tautomer (shown in Scheme 1)
and selenenol tautomer (not shown).Fig. 1 Hqasesc distribution diagram. Species notation as in Scheme 1.Description of the solid-state structures
A summary of data collection and renement parameters for
Hqasesc and 1 is given in Table 2. The molecular structure of
Hqasesc is presented in Fig. 2, and selected bond lengths and
bond angles are presented in Table 3.
Validation of the Hqasesc structure with MERCURY CSD44
shows no signicant deviation from the common values found
in the Cambridge Structural Database.45 Thus, the structural
parameters of Hqasesc are quite usual for this arrangement of
sp2 hybridized atoms. It is evident that electron delocalization is
pronounced throughout the whole ligand molecule, and only
the C2–N2 distance corresponds to a localized double bond. It is
interesting to note that the ligand is comprised of two nearly
planar parts – the quinoline aldehyde moiety and the seleno-
semicarbazide moiety – which are mutually inclined at
20.38(10). Moreover, the molecule adopts a conformation in
which the quinoline N1 and azomethine N2, as well as the
azomethine N2 and Se1 atoms are mutually in trans positions.
This implies that conformational rearrangement is necessary
for metal binding in the expected and observed tridentate way.
Molecular arrangement in the crystal structure of the ligand is
governed by a network of hydrogen bonds formed between N4
and N1 and N3 and Se1 (Fig. S13 and Table S1, ESI†) so that
molecules are grouped into sheets parallel to the (101) crys-
tallographic plane.
The asymmetric part of the unit cell in the crystal structure of
1 is comprised of the complex cation [Zn(Hqasesc)2]
2+ (Fig. 3),
two perchlorate anions and one ethanol molecule. Important
structural parameters are collected in Table 3. The complex
cation has approximately C2 symmetry (pseudo-symmetry axis
is the bisector of N1–Zn1–N1A angle) and is comprised of two
meridionally placed ligand molecules chelating the Zn(II) atom.
Hqasesc molecules are coordinated in their neutral forms as
tridentate NNSe donors, through the quinoline and azomethineTable 1 Acidity constant values of Hqasesc (pKa1 and pKa2), given as
mean pKa value  conﬁdence interval (CI) at 95% probability
Wavelength (nm) pKa1
Wavelength
(nm) pKa2
287 3.52 266 7.16
327 3.43 330 7.18
341 3.40 365 7.08
390 3.42
Average  CI 3.44  0.08 7.14  0.13
95194 | RSC Adv., 2015, 5, 95191–95211nitrogen atoms, and selenium atom. This coordination mode of
the ligand is already observed in Ni(II) and Co(III) complexes
of the formula [Ni(qasesc)2]$DMSO26 and [Co(qasesc)2]
BF4$2H2O,46 and as expected, it is analogous to NNS coordina-
tion of structurally related thiosemicarbazones.47–49 In that way,
each ligand forms two ve-membered metallocycles and all
show a high degree of planarity. The exception is ve-membered
metallocycle Se1–Zn1–N2–N3–C1, which is signicantly puck-
ered, and may be described as twisted on the Zn1–N2 bond. The
coordination octahedron is distorted, as a consequence of
constraints implied by the ligand’s bite angles which are in the
range 73.74(7)–79.44(5).
Metal–ligand bonds fall in a wide range (2.1808(18)–
2.6233(3) A˚), which is in line with the diﬀerent covalent radii of
nitrogen and selenium donor atoms. Quinoline nitrogen atoms
form slightly longer bonds than azomethine nitrogen atoms,
which is also observed in Ni(II) and Co(III) complexes with
Hqasesc.26,46 On the other hand, signicantly longer bonds are
formed between Se and Zn atoms, as expected. It is worth
mentioning that Zn–Se bonds are not equivalent, and that the
Se1 atom forms an almost 0.1 A˚ longer bond [2.6233(3) A˚]
compared to Se1A [2.5592(3) A˚]. Moreover, the Se1 atom is part
of the only signicantly puckered metallocycle. Ligand defor-
mation occurs in a way that the distance between Se1 and Se1A
is maximized (Se1/Se1A ¼ 3.8831(3) A˚). This can be visualized
by torsion angles s(C2–N2–N3–C1) ¼ 169.7(2), and s(N2–N3–
C1–Se1) ¼ 6.9(3). Similar behavior is observed in
[Ni(qasesc)2], where the Se/Se distance is 3.7955(5) A˚ however,
in that complex, both ligands are equally deformed, whereas in
[Zn(Hqasesc)2]
2+ only one ligand is deformed. A proposed
plausible explanation is that the that bis-ligand structure of the
cation places two selenium atoms closer than the sum of their
van der Waals (vdW) radii (rSe ¼ 1.9 A˚), and distortion is the
consequence of steric repulsion.26 Nevertheless, in [Co(qasesc)2]
BF4$2H2O and Fe(III) complex [Fe(L)2][FeCl4]$1/3MeCN (HL ¼ 3-
azabicyclo[3.2.2]nonane-3-carboselenoic acid, [1-(2-pyridinyl)
ethylidene]hydrazide)50 the Se/Se distances [3.349(1) and
3.494(3) A˚, respectively] are signicantly less than the sum of their
vdW radii. The comparison of M–Se bond lengths and Se/SeThis journal is © The Royal Society of Chemistry 2015
Table 2 Pertinent crystallographic and reﬁnement data for Hqasesc and 1
Hqasesc 1
Molecular formula C11H10N4Se C24H26Cl2N8O9Se2Zn
Formula weight 277.19 864.72
Temperature (K) 294(2) 294(2)
Habitat Irregular Block
Color Orange Red
Crystal size (mm3) 0.47  0.37  0.21 0.70  0.54  0.30
Crystal system Monoclinic Monoclinic
Space group P21/n P21/c
a (A˚) 8.19022(13) 11.14856(17)
b (A˚) 11.07458(14) 13.88140(18)
c (A˚) 12.09766(18) 20.8541(3)
b () 92.6837(13) 98.5190(15)
V (A˚3) 1096.09(3) 3191.73(8)
Z 4 4
Dcalc (Mg m
3) 1.68 1.80
m (mm1) 3.402 3.281
q range () 3.0–29.0 3.1–32.5
Reections collected 19 948 55 626
Independent reections, Rint 2714, 0.023 10 890, 0.021
Reections with I > 2s(I) 2368 8743
Parameters, restraints 157, 0 435, 9
Goodness-of-t on F2 1.206 1.072
R, wR (I > 2s(I)) 0.025, 0.034 0.037, 0.052
R, wR (all data) 0.075, 0.104 0.102, 0.109
Dr max and min (e A˚3) 0.47, 0.31 0.84, 0.59
Fig. 2 ORTEP drawing of molecular structure of Hqasesc at 50%
probability level.
Table 3 Selected bond lengths (A˚) and bond angles () of Hqasesc
and 1
Hqasesc 1
Zn1–Se1 — 2.6233(3)
Zn1–Se1A — 2.5592(3)
Zn1–N1 — 2.2211(17)
Zn1–N1A — 2.2177(17)
Zn1–N2 — 2.1971(18)
Zn1–N2A — 2.1808(18)
C2–N2 1.278(3) 1.275(3)
C2A–N2A — 1.271(3)
N2–N3 1.364(3) 1.355(3)
N2A–N3A — 1.362(3)
C1–N3 1.348(3) 1.339(3)
C1A–N3A — 1.340(3)
C1–Se1 1.841(2) 1.842(3)
C1A–Se1A — 1.842(2)
N1–Zn1–N2 — 73.74(7)
N1A–Zn1–N2A — 74.02(7)
N2–Zn1–Se1 — 77.84(5)
N2A–Zn1–Se1A — 79.44(5)
N1–Zn1–Se1 — 149.70(5)
N1A–Zn1–Se1A — 152.98(5)
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View Article Onlinedistances above mentioned shows that these properties are
approximately in direct proportion. Since Se/Se distances in
Co(III) and Fe(III) complexes are shorter than the sum of the vdW
radii, it appears that in these cases the strength of the coordi-
nation bonds compensate the steric repulsion, whereas in Ni(II)
and Zn(II) complexes the longer metal–ligand bonds allow
deformation of the coordination polyhedron to minimize steric
repulsion between non-bonded adjacent Se atoms.
Intra-ligand bond lengths in the structure of 1 are quite
similar to those found in the free ligand. A CSD search for C–Se
single and double bond length distribution in Se-coordinated
compounds having a N–C(–Se)–N fragment, reveals very broad
and overlapped ranges: 1.81–1.93 A˚ (67 hits, mean ¼ 1.87(2) A˚)
for formal double bonds, and 1.81–1.97 A˚ (58 hits, mean ¼
1.88(3) A˚) for formal single bonds. In this context, Se1–C1 and
Se1A–C1A bond lengths in the complex (1.842(3) and 1.842(2) A˚,
respectively) are slightly shorter than the average C]Se double
bond in compounds with structurally related fragments.This journal is © The Royal Society of Chemistry 2015Overall the crystal structure is comprised of interleaved
cation sheets and anion + solvent sheets, progressing parallel to
the ac plane (Fig. S14, ESI†). In addition to the electrostatic
attraction, cations and perchlorate anions are connected with
numerous hydrogen bonds. The two selenosemicarbazone
moieties of a cation are diﬀerently involved in these interactions
as hydrogen bond donors. Namely, N(4)H2 and N(3)H groupsRSC Adv., 2015, 5, 95191–95211 | 95195
Fig. 3 The ORTEP diagram of complex cation [Zn(Hqasesc)2]
2+ in 1
drawn at 50% probability level.
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View Article Onlineare bonded exclusively to perchlorate oxygen atoms, whereas
N(4A)H2 and N(3A)H groups are bonded to ethanol oxygen,
while the N(4A)H2 group is additionally bonded to another
perchlorate anion. The only signicant cation–cation interac-
tion within the sheet is the weak N4A–H4D/Se1iii (iii:x, y,1/
2) hydrogen bond (Table S1, ESI†). The hydroxyl group of the
ethanol molecule exhibits positional disorder, and in both sites
(O9A and O9B) it acts as a N(3A)H hydrogen bond acceptor, but
acts as a hydrogen bond donor to perchlorate anions in oppo-
site directions.
Free radical-scavenging activity
Because selenium antioxidants can prevent oxidative damage,
numerous animal and clinical trials have investigated the
ability of these compounds to prevent the oxidative stress that is
an underlying cause of cancer. Interest in selone (C]Se) anti-
oxidants can be attributed to naturally occurring selenoneine,
a compound which eﬀectively scavenges the 1,1-diphenyl-2-
picrylhydrazyl (DPPH) radical.51 In our previous study the free
radical-scavenging activity of selenosemicarbazones and their
metal complexes by the ABTS [2,20-azino-bis(3-ethyl-
benzothiazoline-6-sulphonic acid)] method were determined.14
Our results showed that Hqasesc and its isomeric analogue
H8qasesc (8-quinolinecarboxaldehyde selenosemicarbazone)
had an excellent ABTS cation radical-scavenging eﬀect, which
was greater than that of reference antioxidant vitamin C.
Coordination to Pt(II), Pd(II), Cd(II), Co(III) and Ni(II) reduced the
antioxidant activity in the corresponding complexes. However,
some selenosemicarbazone complexes still showed better
activity than vitamin C.1495196 | RSC Adv., 2015, 5, 95191–95211The proton donating ability of Hqasesc and 1 was assayed
using a protocol for the determination of radical scavenging
activity, the DPPH method.52 IC50 values were calculated from
the plotted graph of scavenging activity against the concentra-
tions of the samples. IC50 is dened as the total antioxidant
necessary to decrease the initial DPPH radical by 50%. IC50 was
calculated for all compounds based on the percentage of DPPH
radicals scavenged. Ascorbic acid was used as the reference
compound (positive control) with concentrations from 50 to 500
mg mL1. These results corroborate our previous nding ob-
tained by the ABTS method that Hqasesc has excellent free
radical-scavenging activity, better than vitamin C. Coordination
to Zn reduces the activity of the corresponding complex 1, but
still 1 is two times more active than vitamin C.Evaluation of pro-apoptotic activity
An initial experiment was organized to test the ability of Hqa-
sesc and 1 to induce cell death in treated malignant pop-
ulations. Both compounds were applied in a range of six
concentrations and le for 24 h on THP-1 and AsPC-1 cells.
Aerwards, cells were evaluated for the occurrence of cell death
in terms of quality and quantity. There are several modalities of
cell death that are classied according to morphological char-
acteristics and measurable biochemical features.53 In the
current study Annexin-V/propidium iodide (PI) staining was
used, i.e. a quantitative method that provides objective assess-
ment of cell viability alongside an accurate incidence of
apoptotic and necrotic cells in the analyzed sample. This
method is based on detection of phosphatidylserine (PS)
externalization in the plasma membrane surface of apoptotic
cells. This is the earliest event in this programmed cell death
arisen as one of the “eat-me” signals that contributes to the
recognition and removal of apoptotic bodies by phagocytosis.54
The PS is also a binding site for Annexin-V, while PI serves as
a cell membrane non-permeant dye excluded from viable cells.
Such double assay staining allows diﬀerentiation between
viable cells and those in apoptosis: early (Annexin-V positive
cells), late stages (Annexin-V and PI positive cells) and necrosis
(PI only stained cells).
As represented in Fig. 4, both compounds on THP-1 cells
induced a concentration-dependent increase in percentage of
apoptotic cells, while appearance of necrosis was at the level of
untreated control. In cells treated with Hqasesc, apoptosis was
detected starting from a concentration of 30 mM, which also was
the concentration that induced the highest percent of double-
stained cells. An increase of Hqasesc concentration on treated
cells was followed by rise of early apoptotic events and
sequential reduction of cells in late apoptosis, whereas
percentages of vital cells remained almost the same in samples
treated within the range 30–75 mM. Treatment with 1 induced
massive apoptosis already at a concentration of 10 mM. It is
interesting that at this concentration almost all apoptotic cells
were in the late stages whereas the incidence of pre-apoptotic
events was barely above the non-treated control. As the
concentration of 1 was increased, the percentage of early
apoptotic cells increased at the expense of viable cells while theThis journal is © The Royal Society of Chemistry 2015
Fig. 4 Activity of Hqasesc, 1 and CDDP on THP-1 cells. Annexin-V and
PI double staining (left panels for apoptosis) and PI single staining (right
panels for cell cycle) of THP-1 cells after 24 h treatment with Hqasesc,
1 and CDDP applied in a range of six dose concentrations. In Annexin-
V/PI plots cells are discriminated as viable (non-stained cells, lower left
quadrant), cells in early phases of apoptosis (Annexin-V single stained
cells, lower right quadrant), cells in late phases of apoptosis (double-
stained cells, upper right quadrant), and cells in necrosis (PI single
stained cells, upper left quadrant). The same cells evaluated with
Annexin-V/PI were ﬁxed in ethanol right after analysis, left overnight
and assayed the next day for cell cycle phases of mitotic division with
the PI single staining method after RNAse treatment. Frequency of
cells found in G0/G1, S and G2/M phases was determined according to
non-treated control population. All results are expressed as themean%
 SD of two replicates from independent experiments, while
compounds were placed on the same microtiter plate in both
experiments with the same non-treated control for Annexin-V/PI and
cell cycle analysis.
Fig. 5 Activity of Hqasesc, 1 and CDDP on AsPC-1 cells. Annexin-V
and PI double staining (left panels for apoptosis) and PI single staining
(right panels for cell cycle) of AsPC-1 cells after 24 h treatment with
Hqasesc, 1 and CDDP applied in a range of six dose concentrations. In
Annexin-V/PI plots, cells are discriminated as viable (non-stained cells,
lower left quadrant), cells in early phases of apoptosis (Annexin-V
single stained cells, lower right quadrant), cells in late phases of
apoptosis (double-stained cells, upper right quadrant), and cells in
necrosis (PI single stained cells, upper left quadrant). The same cells
evaluated with Annexin-V/PI were ﬁxed in ethanol right after analysis,
left overnight and assayed the next day for distribution within phases of
mitotic division with the PI single staining method in the presence of
RNAse. The frequency of cells found in G0/G1, S and G2/M phases was
determined according to the non-treated control population. All
results for Hqasesc and 1 are expressed as the mean%  SD of two
replicates from independent experiments. Results for CDDP are
expressed as the % of gated cells from one replicate considering the
additional experiment was not performed due to inactivity of CDDP on
AsPC-1 cells. Investigated compounds were placed on diﬀerent plates,
with separate non-treated control cells for Annexin-V/PI reading,
while the control for cell cycle analysis represents the mean%  SD of
ﬁve replicates.
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View Article Onlineincidence of double stained cells remained unchanged.
Contrary to Hqasesc and 1, treatment of THP-1 cells with CDDP
induced only their accumulation at the early phase of apoptosis.
Even the escalation of CDDP concentration could not facilitate
execution and termination of apoptosis aer 24 h of incubation.
It is expected from a successful anticancer agent not only to
trigger apoptotic death, but also to conduct the cells through
the whole process of programmed cell death. If all the chains of
cascaded actions of apoptosis are accomplished within a short
period of time, the treated cell will have less chance to develop
resistance to the mechanism which initiated the apoptotic
response. Therefore, compared to CDDP both Hqasesc and 1
displayed a more favorable mode of activity on the THP-1 cell
line.
Likewise, a striking lack of early apoptotic events was also
evident in AsPC-1 cells treated with 1 (Fig. 5). In these cells the
rst double-stained events were read-out in samples treated
with 1 at 30 mM, and their percentage increased dependent on
the concentration of 1. On the other hand, in AsPC-1 cells
treated with Hqasesc, apoptosis was found only in the sample
treated with the highest applied concentration and was notThis journal is © The Royal Society of Chemistry 2015accompanied by an increased percentage of necrotic cells.
These results le it unclear whether THP-1 and AsPC-1 cells,
labeled with both Annexin-V and PI, aer treatment with 1 were
actually apoptotic or necrotic since it was shown that double-
stained cells can be interpreted as both.55 In order to make
a clear discrimination between apoptosis and necrosis as the
endpoint event of the treatments, we decided to manipulate
these two possible scenarios by using shorter incubation
periods with a single appointed concentration of each
compound. This concentration was chosen to be the ED50
computed according to the percentage of Annexin-V labeled
cells irrespective of the PI positive cells. As seen from dose–
response curves (Fig. S15, ESI†), both Hqasesc and 1 showed
signicantly stronger activities against THP-1 cells, with several
times higher ED50 concentrations on the AsPC-1 cell line. The
ED50 concentration for CDDP on THP-1 cells was comparable to
the value for Hqasesc, but three times higher compared to 1. OnRSC Adv., 2015, 5, 95191–95211 | 95197
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View Article Onlinethe AsPC-1 cell line CDDP did not induce either a signicant
percentage of cell death, or ED50 changes.
Impact on apoptotic responses of co-incubation with the
pancaspase inhibitor Z-VAD-fmk
Apoptosis is a process of biochemical events that lead to char-
acteristic morphological changes of the cell and nally its
death. These biochemical events are predetermined and
include cascaded activations of diﬀerent eﬀectors, starting from
a triggering incidence up to mitochondrial outer membrane
permeabilization, which is marked as the “point of no return” of
the lethal process.53 The central role in regulation of apoptosis
belongs to caspases, a family of cysteine proteases. If caspases
play an essential role in THP-1- and AsPC-1-treated cells, then
the pancaspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(O-
Me) uoromethyl ketone (Z-VAD-fmk) should inhibit the
treatment-dependent response. We performed a 6 h co-
incubation of Z-VAD-fmk with either Hqasesc or 1 applied at
their ED50 concentrations on THP-1 and AsPC-1 cells, respec-
tively, while the eﬀect of Z-VAD-fmk on apoptosis induced by
CDDP was investigated only on the THP-1 cell line. Aer incu-
bation, the cells were stained with Annexin-V/PI, and the
percentages of cell death inhibition were computed taking all
Annexin-V positive events into account (Fig. 6A).
According to the percent of inhibited apoptotic response for
Z-VAD-fmk co-treated cells, all investigated compounds induced
apoptosis by both, caspase-dependent and caspase-
independent pathways. In THP-1 cells, average reduction of
apoptotic death varied from 20 to 35% with no signicant
diﬀerence between treatments. On the contrary, the addition of
Z-VAD-fmk to Hqasesc and 1 treatment on AsPC-1 cells had
higher impact on cell survival as compared to THP-1 cells. These
results indicated that Hqasesc and 1 induce apoptosis in THP-1
and AsPC-1 cell line by diﬀerent pathways. Also, the high
percent of apoptosis reduction by Z-VAD-fmk in AsPC-1 cell line
treated with 1 clearly indicates that double-stained events found
aer 24 h of incubation were cells in advanced phases of
apoptosis rather than necrosis.
Assessment of caspase activity
Results with Z-VAD-fmk imposed the need to assess which
pathway is activated in regulation of apoptotic death by treat-
ment of the cells with Hqasesc and 1. Caspases that regulate
apoptosis can be divided into two major groups: caspase initi-
ators (caspases 2, 8, 9, and 10), and caspase eﬀectors (caspases
3, 6, and 7). Further, apoptosis can be triggered through
diﬀerent biochemical routes, which in general are divided into
“intrinsic” and “extrinsic” pathways.56,57 Briey, the term
“extrinsic apoptotic pathway” indicates that apoptosis is trig-
gered by extracellular death signals that are sensed and prop-
agated by specic transmembrane receptors, a pathway
regulated by caspase-8 or -10. Initiation of the “intrinsic
apoptotic pathway” comes as a result of bioenergetics and
metabolic catastrophe triggering caspase-9. Therefore, we
evaluated caspase-8 and -9 activities aer 6 h of treatment at
ED50 concentrations of Hqasesc and 1 in both cell lines.95198 | RSC Adv., 2015, 5, 95191–95211Non-treated THP-1 cells show a constitutive caspase-9
activity, while activated caspase-8 was never recorded. Aer 6
h of treatment with Hqasesc, only a modest increase in caspase-
9 activity was found whereas activity of caspase-8 stayed on the
level of non treated cells (Fig. 6B). Incubation of THP-1 cells
with 1 and CDDP did not induce increase any activity of these
two caspases. Such a result in the case of CDDP might be quite
understandable considering it induced only a small percentage
of cells in the advanced phase of apoptosis, in correspondence
to the percentage of apoptosis inhibited with Z-VAD-fmk co-
treatment. However, as already discussed above, treatment of
THP-1 cells with 1 induced a massive apoptotic response of low
ED50 value with almost 40% of apoptosis inhibited by Z-VAD-
fmk. All these facts indicate that there is probably another
caspase-dependent pathway of apoptosis regulation involving
another caspase rather than caspase-8 and -9. For instance
caspase-2 should be taken into consideration. A lack of known
caspase-2 substrates has been the major obstacle for its cate-
gorization within one of the two major apoptotic pathways.
Caspase-2 is activated by cellular stress induced by DNA
damage, cytoskeletal disruption or radical oxygen species
formation, and it acts in functional compensation with caspase-
9.58 Thus, further investigation will be required to identify the
possible role of caspase-2 in THP-1 cell apoptosis induced by
Hqasesc and 1.
Constitutive activity of caspase-9 is also found in AsPC-1
cells. Again, incubation with Hqasesc resulted in a slight
increase of caspase-9 and -8 activities (Fig. 6C). On the contrary,
treatment with 1 triggered massive activation of both caspases.
Such a result conrms that complex 1 is a strong apoptotic
inducer for AsPC-1 CSCs. Nevertheless, considerable impact of
Z-VAD-fmk on apoptosis induced by Hqasesc indicates a possi-
bility that its activity on AsPC-1 cells might also be related to the
activation of caspase-2, rather than caspase-8 and -9.Cell cycle distribution
In the current study certain improvements of the standard
experimental protocols were applied. In particular, cells treated
for 24 h and stained with Annexin-V/PI for evaluation of pro-
apoptotic activity, aer analysis on ow cytometer, were xed
overnight with ethanol and subsequently assessed for cell cycle
distribution. This manipulation brought considerable advan-
tages such as the decrease in amount of analyses, and more
importantly the reduction of incidental divergences in experi-
mental results since the same treated cells were used to provide
two diﬀerent but complementary read-outs.
As represented in Fig. 4, Hqasesc and 1 stimulated THP-1
cells arrest in the S phase of mitotic division in a concentra-
tion-dependent manner. This phenomenon coincided with
the occurrence of apoptosis. In AsPC-1 cells treatment with
Hqasesc and 1 induced arrest at the S phase only at the lowest
concentration of 1 mM, which, following an increase of applied
concentrations, was shied toward G1-to-S blockage (Fig. 5).
Thus, the incidence of apoptosis in AsPC-1 cells could not be
related to a particular alteration in cell distribution within
mitotic division. Interestingly, CDDP on THP-1 cells initiallyThis journal is © The Royal Society of Chemistry 2015
Fig. 6 (A) Percent of apoptosis inhibition induced by 6 h co-incuba-
tion of Hqasesc (white bar), 1 (black bar) and CDDP (gray bar) applied in
ED50 concentrations with pancaspase inhibitor Z-VAD-fmk. Results
are expressed as the mean  SD of two replicates from independent
experiments. The role of caspases in apoptosis induced by Hqasesc, 1
and CDDP. Caspase-8 and -9 activities determined in cells after 6 h
incubation with Hqasesc, 1 and CDDP on THP-1 cells (B) and Hqasesc
and 1 on AsPC-1 cells (C), all applied in ED50 concentrations. In the
plots cells are discriminated as live (not stained with either caspase nor
7-AAD), mid stage apoptotic cells (cells stained with either caspase-8
or -9, but negative to 7-AAD), late stage apoptotic cells (cells stained
with either of caspase-8 or -9 and with 7-AAD), and necrotic cells
(cells not stained with either caspase-8 nor -9, but positive for 7-AAD).
This journal is © The Royal Society of Chemistry 2015
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View Article Onlineinduced S-to-G2 arrest at the lowest applied concentration,
shiing to a blockage in the S phase at 3 mM, and nally
generated G1-to-S arrest, which matches with apoptotic
response (Fig. 4). These results indicate the following: Hqasesc
and 1 have diﬀerent modes of activity on THP-1 compared to
CDDP, and Hqasesc and 1 induce apoptosis in THP-1 and AsPC-
1 cells by dissimilar mechanisms. One might suppose that
Hqasesc and 1 in THP-1 cells interfere with DNA replication,
while in AsPC-1 cells they initiate activation of G1/S checkpoints
which impedes cell transition into the S phase and the begin-
ning of DNA replication. To determine the ability of the more
active compound (1) to interact with DNA, the next set of
experiments on DNA binding and DNA cleavage were
performed.
DNA binding studies
Non-covalent interactions of transition metal complexes with
DNA include intercalation between the bases, binding to minor
groove, major groove, sugar-phosphate backbone and three-way
junction.59 Electronic absorption spectroscopy is an eﬀective
method for examining the binding mode. The hypochromic
eﬀect induced by the DNA on a spectrum of a bound ligand is
one indicator of the binding mode. In general, intercalators
have stronger hypochromicities than the corresponding groove
binders. The absorption spectra of metal complexes bound to
DNA through intercalation exhibit signicant hypochromism
and red shi due to the strong p / p* stacking interaction
between the aromatic chromophore ligand of the metal
complex and the base pairs of DNA.60 Metal complexes, which
bind non-intercalatively or electrostatically with DNA, may
result in either hyperchromism or hypochromism.61 Groove
binding typically results in only subtle changes in the structure,
and DNA remains essentially in an unperturbed B form. In
contrast, intercalation in which a planar ligand moiety is
inserted between adjacent base pairs, results in a substantial
change in DNA structure and causes lengthening, stiﬀening and
unwinding of the helix. Zinc-containing compounds are regar-
ded as one of the most promising alternatives to CDDP as
anticancer drugs.62 It has been reported that zinc complexes can
interact with DNA by diﬀerent modes.63,64 In this work, spec-
troscopic methods were employed to ascertain the interaction
mode of 1 with calf thymus (CT) DNA.
Electronic absorption spectra of 1 in aqueous buﬀer media,
both in the absence and the presence of CT-DNA, are shown in
Fig. 7. The absorption spectrum of 1 (Fig. 7A) exhibits two peaks
(at 296 and 343 nm) and two shoulders (at 240–250 and 425–450
nm). The interaction of the complex with CT-DNA was moni-
tored by the disappearance of shoulder bands and peak at 296
nm. Aer interaction with CT-DNA, the absorption band at 343
nm exhibited hyperchromism of about 22% with the lowest
concentration of 1. With the increase of concentration of 1 (3 
105 and 6  105 M), hypochromism (the value reaches 26%
and 50%, respectively) followed by blue shi (10 nm at maximalResults are expressed as the mean%  SD of two replicates from
independent experiments.
RSC Adv., 2015, 5, 95191–95211 | 95199
Fig. 7 Determination of binding constant by absorption titration of 1
with CT-DNA. (A) Absorption spectra of CT-DNA (8.81  107 M, –$–$
CT-DNA), 1 (1, 3, and 6  105 M, — complex 1) and CT-DNA in
presence 1, 3, and 6  105 M of the complex (— 1/CT-DNA). (B)
Absorption spectra of 1 (3 105 M) without (0 M) and with CT-DNA at
diﬀerent concentrations (2.202, 4.405, 6.607, 8.81, 11.01, 13.21, 15.41
and 17.62  105 M); (C) plot of [DNA]/(3A  3F) versus [DNA].
Fig. 8 Displacement of DNA-bound ethidium bromide (EB) by 1. (A)
Emission spectra (lex ¼ 500 nm) of EB (2.5  105 M) bound to CT-
DNA (1  104 M, top line) and quenching of EB–CT-DNA system by 1
at increasing concentrations (0 to 3  105 M, curves from top to
bottom). The arrow shows that ﬂuorescence intensity decreased with
increasing concentration of the complex. The inset demonstrates the
saturation of binding. (B) Fluorescence quenching curves of EB bound
to CT-DNA at lmax ¼ 600 nm by 1; r ¼ [1]/[CT-DNA].
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View Article Onlineperformed concentration), occurs as the result of possible
intercalative interactions between the complex and CT-DNA due
to the strong stacking interaction between the aromatic chro-
mophore of 1 and the base pairs of DNA.
In the spectra of Zn(II)-complex/CT-DNA, a peak at 258 nm
was also observed with an increase in absorption intensity,
Fig. 7A (hyperchromism was calculated as 57%, 64% and
72%). The absorption intensity at 258 nm was increased due
to exposure of purine and pyrimidine bases due to complex
binding. In order to obtain information on aﬃnity of 1 for CT-
DNA, a spectroscopic titration of the solution of the complex
with an increasing concentration of CT-DNA was performed
(Fig. 7B). The absorbance at 258 nm was monitored for each
concentration of DNA. The intrinsic binding constant KB of the
complex (Fig. 7C) was calculated as 8.92  104 M1 (for calcu-
lation details see Experimental section). The value of binding
constant was lower than reported for a classical intercalator, i.e.
a range from 106 to 107 M1.65 The value of KB for 1 was
comparable to those for other metal complexes,64,66 suggesting
minor groove binding of 1. The spectral changes that occur
when 1 was added to CT-DNA, as well as the absence of iso-
sbestic points in these spectra, suggest that more than a single
binding mode can occur.95200 | RSC Adv., 2015, 5, 95191–95211In order to further investigate the binding mode, uores-
cence analyses were performed. Upon excitation at p / p*
transitions either in DMSO or in the presence CT-DNA, 1 did not
emit luminescence. Hence, indirect evidence for the binding
mode was examined by uorescent displacement experiments,
carried out with two diﬀerent dyes: ethidium bromide (EB),
a typical DNA intercalator and Hoechst 33258 (H), a minor
groove binder. It is known that EB interacts with CT-DNA in the
intercalation mode with strong binding aﬃnity.67 The extent of
the uorescence quenching of EB by competitive displacement
from DNA is a measure of the strength of the interaction
between the second molecule and DNA.68 Binding of EB to CT-
DNA was followed by excitation at 500 nm with a maximum in
uorescence at 600 nm. The emission spectra of EB bound to
CT-DNA in the absence and presence of 1 are given in Fig. 8. A
continuous decrease was observed in uorescence intensity at
600 nm for EB–CT-DNA with increasing concentration of 1 (up
to 22 mM, see Experimental section). It was shown that the
complex quenches the uorescence probe with the maximal
decrease in the uorescence intensity of the EB–CT-DNA by
18%, followed by saturation at a high concentration of 1 (14 mM)
(Fig. 8A and the inset). Fig. 8B shows that the obtained uo-
rescence quenching data gives a linear plot in accordance with
the Stern–Volmer eqn (6) (see Experimental section). The uo-
rescence quenching constant (Ksv) value was calculated from the
ratio of the slope to the intercept from the plot of I0/I versus r
(ratio of concentrations of complex 1 and CT-DNA, r ¼ [1]/[CT-
DNA]) as Ksv ¼ 1.802. The observed saturation at high concen-
trations of 1 indicated that 1 quenches the uorescence of EB–
CT-DNA by displacement of bound EB in a limited fraction of
binding sites.
To further clarify the interaction of 1 with DNA, uorescent
displacement experiments with H dye were performed. H pref-
erentially binds in the minor groove at A:T-rich sequences in B-
DNA at the edges of four to ve contiguous base pairs with
nanomolar aﬃnity.69This journal is © The Royal Society of Chemistry 2015
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View Article OnlineAlso, an unspecic weaker binding at a high [H]/[DNAbp]
ratio has to be considered.70 Fig. 9A shows the characteristic
emission spectrum of H when it is bound to CT-DNA. The
addition of 1 to CT-DNA caused appreciable reduction in the
uorescence intensity of the H–CT-DNA system in a concentra-
tion dependent way. The quenching of H–CT-DNA showed an
initial saturation at 10 mMconcentration of 1 (inset in Fig. 9A). It
is important to note that the uorescence intensity was reduced
to nearly half of the initial value. The half-reciprocal plot of the
quenching data according to the Stern–Volmer equation resul-
ted in a linear plot with a quenching constant Ksv ¼ 6.43. The
value of quenching constant Ksv was calculated from the ratio of
the slope to the intercept from the plot of I0/I versus r (r ¼ [1]/
[CT-DNA]) (Fig. 9B). With increasing concentration of 1, an
additional decrease in uorescence intensity was observed,
followed by saturation in competitive displacement from the H–
CT-DNA system.
The obtained results of the extent of the uorescence
quenching of EB by competitive displacement from the EB–CT-
DNA system and groove binder H from the H–CT-DNA system
demonstrated that 1 non-selectively binds to DNA, exhibiting
both binding modes. Comparing Ksv values for the quenching
uorescence intensity by displacement it may be concluded that
1 was more eﬃcient as a groove binder than as an intercalator.
The results are in agreement with UV-Vis spectrophotometry
data.
Considering that the electrostatic interaction between the
positively charged complex cation [Zn(Hqasesc)2]
2+ and the
negatively charged phosphate backbone may occur, with
respect to the geometry of the complex, it can be concluded that
optimal interaction can include partial intercalation of
aromatic rings in the minor groove of the double helix of CT-
DNA. This mode of interaction with DNA by partial intercala-
tion and specic minor groove binding was earlier described for
bleomycins.71Fig. 9 Displacement of DNA-bound Hoechst 33258 (H) by 1. (A)
Emission spectra (lex¼ 350 nm) of H (2.8 105 M) bound to CT-DNA
(1  104 M, top line) and quenching of H–CT-DNA system by 1 at
increasing concentrations (0 to 4  105 M, curves from top to
bottom). The arrow shows that ﬂuorescence intensity decreased with
increasing concentration of the complex. The inset demonstrates the
saturation of binding. (B) Fluorescence quenching curves of H bound
to CT-DNA at lmax ¼ 440 nm by 1; r ¼ [1]/[CT-DNA].
This journal is © The Royal Society of Chemistry 2015Plasmid DNA interaction study
The ability of 1 to cleave double-stranded plasmid DNA in the
absence of any reducing agents was investigated using an
electrophoretic analysis. As is shown in Fig. 10 (lane 1), plasmid
pUC19 consists mainly of supercoiled form FI and nicked form
FII. DMSO did not show any eﬀect on plasmid DNA in the
performed experimental conditions (Fig. 10, lane 2). Upon
addition of an increasing concentration of 1 to the plasmid,
a gradual diminishing of the supercoiled form FI and nicked
form FII was observed (Fig. 10, lanes 3–6) and the forms dis-
appeared at a much higher concentration of 1 (35 and 40 mM,
lanes 7 and 8, respectively). The possible multimer forms with
very slow mobility were observed (remained at the start of run).
The generation of the multimer was concentration dependent
indicating that 1 does not possess nuclease activity. A possible
cause for aggregation can be formation of multiple hydrogen
bonds between the complex cation and phosphate moieties in
the plasmid DNA. Such multiple hydrogen bonds were observed
in the crystal structure between the complex cation and
perchlorate anion, which like phosphate, has a tetrahedral
geometry.Interaction between 1 and human serum albumin (HSA)
The interaction between 1 and HSA has been studied by UV-Vis
and uorescence spectroscopy. The UV-Vis spectra of HSA with
increasing amounts of 1 showed a blue lmax shi (from 280 to
271 nm, Fig. 11A). The results indicate interaction between HSA
and 1, leading to changes in the protein structure upon ligand
binding. The changes in uorescence emission spectra of HSA
with increasing amount of 1 are shown on Fig. 11B.
As the concentration of 1 increases, the results may deviate
from initial linearity due to an instrumental inner lter eﬀect.72
In order to overcome this problem, absorbance wasmeasured at
excitation (280 nm) and emission (340 nm) wavelengths, and
uorescence intensities corrected according to the LakowiczFig. 10 Agarose gel electrophoresis of cleavage reaction of pUC19 by
1. The cleavage reaction was investigated by incubation for 90 min of
512 ng plasmid in 20 mL of 40 mM bicarbonate buﬀer (pH 8.4) at 37 C,
with diﬀerent concentrations of 1. Lane 1 – control plasmid pUC19;
lane 2 plasmid pUC19 with DMSO (20% ﬁnal); lanes 3–8: pUC19 with
0.015, 0.02, 0.025, 0.03, 0.035, and 0.04 mM concentration of 1,
respectively.
RSC Adv., 2015, 5, 95191–95211 | 95201
Fig. 11 Changes in UV-Vis absorption spectra (A) and ﬂuorescence
emission spectra (B) of HSA (c ¼ 5  107 M) in PBS buﬀer (1 PBS, pH
7.35) upon addition of 1 in the following concentrations (106 M): (a)
0.0; (b) 0.34; (c) 0.68; (d) 1.36; (e) 2.04; (f) 3.06; (g) 4.08; (h) 5.1. The
UV-Vis absorption spectrum of pure complex 1 (c ¼ 5  107 M) is
represented with a dashed line; a magniﬁed part of the original HSA
spectrum around lmax (280 nm) is embedded, with blue shift indicated
by a dashed line.
Table 4 Results of Stern–Volmer plot at diﬀerent temperatures (the
average ﬂuorescence lifetime s0 ¼ 7.09 ns for HSA). Ksv is obtained as
a slope, while intercept is kept constant (¼1)
T (K) 106  Ksv (M1)
1014
 Kq (M1 s1) r2
293 2.01  0.04 2.82 0.995
298 1.91  0.04 2.70 0.994
310 1.51  0.03 2.13 0.993
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View Article Onlineequation73 given in the Experimental part. Corrected uores-
cence intensities were used for further calculations.
Upon addition of an increasing amount of 1, a signicant
decrease of HSA uorescence intensity (uorescence quench-
ing) is observed, as well as a blue shi of the wavelength of
maximum emission (340 nm). This shi indicates that the
microenvironment around Trp 214 is altered as the HSA–1
adduct is formed. In general, uorescence quenching might be
classied as static or dynamic. Dynamic quenching is highly
dependent upon diﬀusion. Higher temperatures result in faster
diﬀusion and hence larger values for bimolecular quenching
constant. On the other hand, higher temperatures will typically
result in the dissociation of weakly bound complexes, and
therefore decrease the bimolecular quenching constant in
a static process. Fluorescence quenching data were processed
using the Stern–Volmer equation74 (for details see Experimental
part) in order to obtain Ksv and Kq, the Stern–Volmer quenching
constant and the quenching rate constant of the protein,
respectively (Fig. S16, ESI†). As can be seen from Table 4, Ksv
decreases as temperature increases, indicating that the
quenching mechanism is static. Another conrmation of the95202 | RSC Adv., 2015, 5, 95191–95211static quenching mechanism is the value of Kq, which is higher
than the maximum scatter collision quenching constant value
(2  1010 M1 s1).75
The quenching process was additionally analyzed using
a modied Stern–Volmer equation73 in order to obtain the
eﬀective quenching constant, Ka, for the accessible uo-
rophores, and the fraction of accessible uorophore fa. The
results are shown in Fig. S17 (ESI†) and in Table 5.
The Ka is inversely correlated with temperature, which is in
accordance with Ksv temperature dependency.
Thermodynamic binding parameters, enthalpy (DH) and
entropy change (DS), for binding of a small molecule to
a protein can be calculated according to the Van’t Hoﬀ equation
(given in the Experimental section) by measuring the binding
constants at several temperatures. The results are shown in
Fig. S18 (ESI†) and in Table 5. According to Ross’ view,76 signs
and magnitudes of thermodynamic parameters for protein
reactions can account for the main forces contributing to
protein stability. From the thermodynamic stand-point, DH >
0 and DS > 0 implies a hydrophobic interaction, DH < 0 and DS <
0 reects the van der Waals force or hydrogen bond formation
and DH < 0 and DS > 0 suggest an electrostatic force. In our case,
DH < 0 and DS > 0, indicates that the electrostatic forces are the
main contributors to HSA–1 binding.
When small molecules bind independently to a set of
equivalent sites of a protein, the equilibrium between free and
bound molecules for the static quenching process is given by
eqn (1):77
log
F0  F
F
¼ log Kb þ n log½Q (1)
where F0 and F are the steady-state uorescence intensities in
the absence and presence of 1; Kb is binding constant, n is the
number of binding sites and [Q] denotes the total concentration
of quencher. Linear dependence is shown in Fig. S19 (ESI†), and
the results of linear t are given in Table 6. As the value of n is
close to 1, it is suggested that 1 binds only to one binding site.
The value of Kb is in the order of 10
6. These results, along with
the previously determined eﬀective quenching constant Ka,
suggest that 1 strongly binds to HSA, so it can be eﬀectively
carried and stored in the human body.
Fluorescence resonance energy transfer (FRET) is a non-
destructive spectroscopic method that can give information
about the distance and relative orientation of the donor (Trp
214, D) and acceptor uorophore (interacting molecule, A). The
resonance transfer is more eﬃcient when spectral overlap ofThis journal is © The Royal Society of Chemistry 2015
Table 5 Results of binding of 1 to HSA obtained using the modiﬁed Stern–Volmer plot; thermodynamic parameters of binding are calculated
using the Van’t Hoﬀ equation
T (K) 106  Ka (M1) fa r2
DH
(kJ mol1)
DG
(kJ mol1)
DS
(J mol1 K1)
293 1.50  0.03 0.973 0.999 11.02 34.64 80.75
298 1.44  0.02 0.972 0.998 35.13
310 1.18  0.01 0.946 0.990 36.03
Table 6 Binding constants and the number of binding sites for the
interaction of 1 with HSA at three temperatures
T (K) log Kb (M
1) n r2
293 5.52  0.16 0.897 0.995
298 5.47  0.18 0.892 0.994
310 5.73  0.25 0.958 0.990
Fig. 12 Binding pattern of 1 to DNA with marked interactions: major
groove (A) and minor groove (B). Color code: green – hydrogen
bonds; grey – aromatic interactions; dark yellow – selenium–p
interactions.
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View Article Onlinedonor emission and acceptor absorption is large (Fig. S20,
ESI†). The distance between D and A, r, could be calculated
using energy transfer eﬃciency, E (ref. 73) (for calculation
details see Experimental part). We have calculated the overlap
integral of the donor emission and the acceptor absorption
spectra (J ¼ 5.87  1015 M1 cm3, Fig. S20, ESI†), the energy
transfer eﬃciency (E ¼ 0.230), the Fo¨rster’s distance at which
energy transfer is 50% eﬃcient (R0 ¼ 2.385 nm), and the D–A
distance (r ¼ 3.098 nm). Since the distances between D and A
are usually in the range 2–8 nm, and the obtained r value obeys
the condition 0.5R0 < r < 1.5R0,73 we may conclude that the
energy transfer between HSA and 1 is highly feasible process.
Molecular docking of 1 with DNA and HSA
To examine the binding of the zinc complex to DNA we used the
DNA duplex of sequence d(CGCGAATTCGCG)2 (for details see
Experimental section). Molecular docking gave conformations
binding to the minor and major groove, with slight preference
for theminor groove (Fig. S21, ESI†). Conformations with lowest
binding energy correspond to the minor groove, and the
diﬀerence between the lowest conformation and one bound to
the major groove has a value of 0.1 kcal mol1. No intercalating
structures were found. The pattern of binding is presented in
Fig. 12. The established interactions between 1 and DNA
nucleotides are hydrogen bonds and aromatic interactions.
This is expected, as 1 consists of coordinated groups that are
hydrogen bond donors, particularly NH2 groups. Aromatic
systems from zinc complexes tend to form CH–p interactions
with DNA bases, along with selenium (Se–p interactions), which
can also form hydrogen bonds with bases. This is in accordance
with the experimental results, as reported that 1 has more
aﬃnity to the minor groove than the major, and measurements
showed no signicant intercalation.
The Zn(II) complex was docked into previously identied
binding sites of HSA (PDB IDs 2BXD and 4L9Q, see Experi-
mental part for details), but obtained values of binding energies
were not in accordance with experimental results, as they were
too high or showing low binding aﬃnity. Therefore we decidedThis journal is © The Royal Society of Chemistry 2015to search the whole conformational space of HSA (PDB ID 1BJ5)
which gave an insight into other possible binding sites.
According to the reported thermodynamic properties of ligand
binding, we selected one conformation that was in the best
accordance with the experiment, at the same time having the
lowest binding energy, with value Eb ¼ 36.38 kJ mol1. As
presented in Fig. 13, the main electrostatic interaction is
formed with Glu 354, having in mind that the complex cation
is +2 charged and electrostatic eﬀects are transmitted through
organic ligands coordinated to Zn(II). Also, nitrogen atoms of
Arg 209 and Lys 351 and selenium atoms are suﬃciently close,RSC Adv., 2015, 5, 95191–95211 | 95203
Fig. 13 The Zn(II) complex in the binding site of HSA (PDB ID 1BJ5),
with marked amino acid residues and interactions. Green: hydrogen
bonds; grey: hydrophobic/aromatic interactions.
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View Article Onlineso the electrostatic interaction with partially positive hydrogen
atoms on the residues cannot be neglected, and this is in
accordance with the reported DH < 0. The rest of the interac-
tions are of hydrophobic type, CH–p and aromatic, including
interaction of residues Leu 347, Phe 206, Ala 210, Val 482, Leu
481, and aliphatic chain of Lys 351 with aromatic rings of the
ligand. This conrms the reported DS > 0 value. Also, the re-
ported binding site is not far away from the earlier reported
binding site II,78 as it is close to Trp 214 (Fig. S22, ESI†). The
interactions and distances with the ligand are presented in
Table S2 (ESI†). According to the docking site results, binding
aﬃnity values and interactions, it can be concluded that this
can be a binding site for the reported compound, and its high
aﬃnity to HAS can be explained.Conclusions
A novel zinc(II) complex with a 2-quinolinecarboxaldehyde
selenosemicarbazone ligand was synthesized and character-
ized. Investigation of biological activity shows that both
compounds are strong apoptosis inducers in THP-1 cells. The
apoptotic induction is concentration-dependent and coincides
with an arrest at the S phase of mitotic division, indicating that
Hqasesc and 1 interfere with DNA replication. Results of DNA
binding and DNA docking experiments conrm our hypothesis,
revealing that 1 not only selectively binds to DNA, but with
a higher aﬃnity for the minor groove, with no signicant
intercalation. Therefore, the lack of caspase-8 and -9 activation
in THP-1 cells treated with 1 is consistent since apoptosis could
be triggered here by caspase-2 cascade aer inhibited DNA
replication. On the other hand, both compounds display less
activity on the AsPC-1 cell line, which one could expect since
those cells are mainly CSCs, being non diﬀerentiated and so
more resistant to most conventional therapeutics. While Hqa-
sesc in AsPC-1 cells induces apoptosis only at the highest95204 | RSC Adv., 2015, 5, 95191–95211applied concentration, treatment with 1 shows a concentration-
dependent apoptotic response, obviously not induced by DNA
drug interaction, considering that treated cells are arrested in
the G1-to-S phase, accompanied by an extensive caspase-8 and
-9 activation. These results indicate that Hqasesc and 1 display
cell phenotype specic activity, which is a desirable character-
istic that might signify cytotoxicity on a wide spectrum of cancer
types. Finally, high aﬃnity of 1 for HSA implies a possible
pharmacokinetic property. The unbound fraction of the drug in
plasma may be the active form, also subjected to metabolic
transformation and excretion. The HSA-bound fraction of the
drug may serve as a depository, slowly releasing it as unbound
active form. A high percentage of HSA-bound drug will then
prolong its half-life, reducing its volume of distribution, and
thus avoid possible interactions with other drugs that compete
for binding to HSA.
Experimental section
Reagents and instrumentation
Selenosemicarbazide (98%) was obtained from Acros Organics
(BVBA, Geel, Belgium). 2-Quinolinecarboxaldehyde and zinc
perchlorate hexahydrate were obtained from Aldrich (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany). All solvents
(reagent grade) were obtained from commercial suppliers and
used without further purication.
Elemental analyses (C, H, N) were performed by the standard
micromethods using the ELEMENTAR Vario EL III CHNS/O
analyzer. IR spectra were recorded on a Thermo Scientic
Nicolet 6700 FT-IR spectrophotometer by the Attenuated Total
Reection (ATR) technique in the region 4000–350 cm1.
Abbreviations used for IR spectra: vs, very strong; s, strong; m,
medium; w, weak. Molar conductivity measurements were
performed at ambient temperature (298 K) on a Crison Multi-
meter MM41. NMR spectral assignments and structural
parameters were obtained by combined use of 1H homonuclear
spectroscopy (2D COSY and NOESY) and multinuclear proton-
detected spectroscopy (2D HSQC, 2D HMBC). The NMR
spectra were performed on a Bruker Avance 500 equipped with
broad-band direct probe. Chemical shis are given on d scale
relative to tetramethylsilane (TMS) as internal standard for 1H
and 13C. Abbreviations used for NMR spectra: s, singlet; dd,
doublet of doublets; ddd, double double doublet. Cyclic vol-
tammetric measurements were performed using an electro-
chemical system CH Instruments (USA). UV-Vis spectra for
acidity constant determination were recorded on a Thermo
Scientic Evolution 60S spectrophotometer (Thermo Fisher
Scientic Inc, Waltham, Massachusetts, USA) in 250–500 nm
range. pH values were measured using a CRISON pH-Burette 24
2S equipped with a CRISON 50 29micro-combined pH electrode
(CRISON INSTRUMENTS, S.A. Spain). For DPPH scavenging
activity, absorbance at 517 nm was measured using a Thermo
Scientic Appliskan. Pro-apoptotic activity was determined on
a Guava EasyCyte™ micro-capillary ow cytometer (EMD Mil-
lipore, Darmstadt, Germany) using the InCyte® soware
package (EMDMillipore, Cat. no. 0500-4120). UV-Vis spectra for
DNA binding studies were recorded on a UV-1800 Shimadzu UV-This journal is © The Royal Society of Chemistry 2015
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View Article OnlineVisible spectrometer operating from 200 to 800 nm in 1.0 cm
quartz cells, while for uorescence measurements a Thermo
Scientic Lumina Fluorescence spectrometer (Finland) equip-
ped with a 150 W xenon lamp was used. A Submarine Mini-gel
Electrophoresis Unit (Hoeﬀer HE 33) with an EPS 300 power
supply was used for DNA cleavage studies. The stained gel was
illuminated under a UV transilluminator Vilber-Lourmat
(France) at 312 nm and photographed with a Nikon Coolpix
P340 Digital Camera through lter Deep Yellow 15 (Tiﬀen, USA).
UV-Vis spectra for HSA binding studies were recorded on
a Thermo Scientic Evolution 60S UV-Vis spectrophotometer,
using a quartz cell with 1.0 cm path length, while uorescence
measurements were performed on a spectrouorometer
Fluoromax-4 Jobin Yvon (Horiba Scientic, Japan), equipped
with a Peltier element for temperature control and a magnetic
stirrer for cuvette, using a quartz cell with 1 cm path length.
Synthesis of Hqasesc
The ligand was synthesized according to the reported proce-
dure.14 Single crystals suitable for X-ray analysis were obtained
by recrystallization of the crude product from EtOH. The
chemical structure of Hqasesc was conrmed by elemental
analysis, IR and NMR spectroscopy. These data are in good
agreement with the data previously reported.14
Synthesis of [Zn(Hqasesc)2](ClO4)2$EtOH (1)
Into the solution of 2-quinolinecarboxaldehyde (0.15 g, 0.96
mmol) and selenosemicarbazide (0.13 g, 0.96 mmol) in EtOH
(20 mL), Zn(ClO4)2$6H2O (0.18 g, 0.48 mmol) was added. The
reaction mixture was reuxed for 30 min and cooled to ambient
temperature. Dark red crystals of 1 were obtained from the
ethanolic solution, ltered oﬀ and washed with cold ethanol
and ether. Yield: 0.28 g (66%). Found: C, 33.5; H, 3.1; N, 12.9.
Calc. for C24H26Cl2N8O9Se2Zn: C, 33.3; H, 3.0; N, 13.0%. IR
(ATR), nmax/cm
1: 3434m (NH2), 3297vs (NH), 3183vs (NH),
3077s (NH2), 1617s (C]N), 1578s (NH), 1511m (CH), 1100vs
(ClO4
). LM (1  103 M, EtOH): 72.0 U1 cm2 mol1. 1H NMR
(500 MHz, DMSO, TMS) [ppm] d: 12.56 (s, 1H, N3H), 9.28 (s, 1H,
N4Hb), 9.14 (s, 1H, N4Ha), 8.86 (d, 1H, C4H, 3J4,3¼ 8.8 Hz), 8.72
(d, 1H, C3H, 3J3,4¼ 8.8 Hz), 8.38 (s, 1H, C9H), 8.19 (dd, 1H, C5H,
3J5,6 ¼ 7.7 Hz, 4J5,7 ¼ 1.1 Hz), 8.13 (dd, 1H, C8H, 3J8,7 ¼ 8.5 Hz,
4J8,6 ¼ 1.3 Hz), 8.01 (ddd, 1H, C7H, 3J7,8 ¼ 8.5 Hz, 3J7,6 ¼ 7.0 Hz,
4J7,5 ¼ 1.1 Hz), 7.83 (ddd, 1H, C6H, 3J6,5 ¼ 7.7 Hz, 3J6,7 ¼ 7.0 Hz,
4J6,8¼ 1.3 Hz). 13C NMR (126 MHz, DMSO, TMS) [ppm] d: 175.86
(C10), 151.04 (C2), 142.42 (C4), 140.71 (C8a), 136.57 (C9), 133.28
(C7), 128.98 (C6), 128.77 (C5), 128.12 (C4a), 123.27 (C8), 119.23
(C3). Numbering of atoms used in NMR is given in Scheme S1
(ESI†).
Direct syntheses of 1 starting from zinc perchlorate and
Hqasesc in EtOH aﬀorded an identical product as the template
synthesis, but in a slightly lower yield.
X-ray crystallography
Single crystal X-ray diﬀraction was performed on an Oxford
Diﬀraction Gemini S kappa geometry diﬀractometer, equipped
with Mo Ka radiation from a sealed tube source, and a SapphireThis journal is © The Royal Society of Chemistry 2015CCD detector. Data collection strategy calculation, data reduc-
tion, cell renement and absorption correction were performed
with the CRYSALISPRO.79 The structure was solved using
SHELXT,80 and rened with anisotropic displacement parame-
ters for all non-hydrogen atoms using SHELXL-2014.81 Program
SHELXLE82 was used as graphical user interface for structure
solution and renement procedures. Hydrogen atoms bonded
to carbon atoms were introduced in idealized positions and
rened using a riding model. Hydrogen atoms bonded to
nitrogen atoms were located by diﬀerence Fourier synthesis,
and rened using distance restraints with Uiso approximated by
1.2Ueq of the parent atoms in Hqasesc, whilst their free isotropic
renement was performed in 1. Hydroxyl group of the EtOH
molecule in 1 showed positional disorder, which was modeled
by rening occupational parameters, and applying distance
restraints. Structure was validated using PLATON,83 and Cam-
bridge Structural Database (CSD) (v. 5.36, updates Nov. 2014)45
using MERCURY CSD.44
Crystallographic data for Hqasesc and 1 have been deposited
with the Cambridge Crystallographic Data Centre as Supple-
mentary publication no. CCDC 1413656 and 1413657,†
respectively.
Cyclic voltammetry
The cell (10 mL) consisted of a three-electrode system, glassy
carbon electrode (inner diameter of 3 mm; CHI 104) an Ag/AgCl
(saturated KCl) reference electrode and Pt counter electrode.
The potential was swept over the range from 2.0 to +1.2 V (vs.
Ag/AgCl) at scan rate of 100 mV s1. Measurements were per-
formed at room temperature with deaeration of solutions by
passing a stream of nitrogen through the solution for 5 min
prior to the measurement and then maintaining a blanket
atmosphere of nitrogen over the solution during the measure-
ment. The potentials were measured in 0.10 M [n-Bu4N]PF6/
DMSO, and are quoted relative to Ag/AgCl reference electrode.
Determination of Hqasesc acidity constants
Acidity constants of Hqasesc were determined by spectropho-
tometric titration at T¼ 298 1 K. The working solution (c¼ 3.1
 105 M) was prepared by dissolving an accurately weighed
dried substance in 5.00 mL of DMSO; 10 mM phosphate buﬀer
(pH ¼ 1.77, I ¼ 0.1 M NaCl) was added up to 100.00 mL. The pH
value was adjusted to 1.65 with conc. HCl. Small volume
increments of 1 M KOH were added stepwise, until pH 11.91
was reached (total volume change at the end of the titration was
lower than 2%). The pH value was continuously measured
during the titration and UV-Vis spectra recorded aer pH value
equilibration. The UV-Vis spectra were recorded against the
phosphate buﬀer as a blank. The pH electrode was calibrated by
standard CRISON buﬀer solutions (pH 4.01, 7.00, and 9.21).
Acidity constants for Hqasesc were calculated according to
transformed forms of classical spectrophotometric equations43
which give linear dependence:
A ¼ AH2Aþ þ
AHA  A
½H3Oþ
 Ka1 (2)RSC Adv., 2015, 5, 95191–95211 | 95205
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View Article Onlineor
ðA AHAÞ  10pH ¼
AH2Aþ
Ka1
 1
Ka1
A (2a)
A ¼ AA þ ðAHA  AÞ  ½H3Oþ  1
Ka2
(3)
or
(A  AHA)  10pH ¼ Ka2  AA  Ka2  A (3a)
where A represents absorbance of certain species (H2A
+, HA, or
A) labeled as subscripts, and Ka1 and Ka2 represent the rst and
second dissociation constant of Hqasesc, respectively.
Free radical scavenging antioxidant assay (DPPH method)
The proton donating ability was assayed using a protocol for the
determination of radical scavenging activity.52 Compounds were
dissolved in pure DMSO and were diluted into ten diﬀerent
concentrations. Commercially available free radical DPPH was
dissolved in methanol at a concentration of 6.58  105 M. Into
a 96-well microplate, 140 mL of DPPH solution was loaded and
10 mL DMSO solution of the tested compounds was added, or
pure DMSO (10 mL) as the control. The microplate was incu-
bated for 30 min at 298 K in the dark and the absorbance was
measured at 517 nm. All the measurements were carried out in
triplicate. The scavenging activity of the compounds was
calculated using the eqn (4):
Scavenging activityð%Þ ¼ Acontrol  Asample
Acontrol
 100 (4)
where Asample and Acontrol refer to the absorbances at 517 nm of
DPPH in the sample and control solutions, respectively.
IC50 values were calculated from the plotted graph of scav-
enging activity against the concentrations of the samples. IC50 is
dened as the total antioxidant concentration necessary to
decrease the amount of the initial DPPH radical by 50%. IC50
was calculated for all compounds based on the percentage of
DPPH radicals scavenged. Ascorbic acid was used as the refer-
ence compound (positive control) with concentrations 50 to 500
mg mL1.
Cell cultures
Acute monocytic leukemia cell line (THP-1, ATCC® TIB-202)
and pancreatic adenocarcinoma cell line (AsPC-1, ATCC®
CRL-1682) were maintained in RPMI-1640 (Life Technologies,
11875-093) and DMEM high glucose (Sigma-Aldrich, D5796) cell
culture media, respectively. Both media were supplemented
with 10% (v/v) fetal bovine serum (FBS, Gibco, Cat. no. 16000-
036) and 1% (v/v) penicillin–streptomycin (10 000 units per mL
and 10 000 mg mL1, Gibco, Cat. no. 15140-130). Cells were kept
at 37 C in an atmosphere containing 5% (v/v) CO2 during their
exponential growth and during the course of experimental
treatments.
The ligandHqasesc and 1were initially dissolved in DMSO to
the stock concentration of 20 mM, whereas CDDP was dissolved
in saline to the stock concentration of 5 mM. Further dilutions95206 | RSC Adv., 2015, 5, 95191–95211to the experimental concentrations applied on the cells have
been done with RPMI-1640 or DMEMmedia immediately before
each experiment, thus the nal concentration of DMSO with
cells treated with the highest applied concentration was 0.5%
(v/v).
Determination of pro-apoptotic activity
THP-1 and AsPC-1 cells were seeded in 96 at bottom well plates
(Corning® Costar®, Cat. no. CLS3596) in a volume of 0.1 mL, at
a density of 10 000 per well. Since the THP-1 cells grow in
suspension, experimental treatments were started within 2 h
aer cell seeding, while plates with seeded AsPC-1 cells were le
overnight to settle. Investigated compounds were added in
a range of six concentrations. As controls, non-treated cells,
cells treated with 0.5% DMSO, and cells treated with Celastrol
(Enzo Life Sciences, Cat. no. ALX-350-332-M025) at 50 mM
concentration were used.
Aer 24 h of incubation, THP-1 cells were centrifuged at an
RCF of 450 g for 10 min, supernatants were discarded, and 0.1
mL of PBS was added to each well. Plates were placed on a plate
shaker for 3 min, aerwards Annexin-V-FITC (ImmunoTools,
Cat. no. 31490013) and propidium iodide (PI, MiltenylBiotec,
Cat. no. 130-093-233) were added in a volume of 3 mL per well,
respectively, and incubated for 15 min in the dark before
cytometry analysis. Post incubation manipulation with AsPC-1
cells included trypsinization (200 mL of trypsin per well,
Sigma-Aldrich, Cat. no. T3924). Subsequent steps with addition
of PBS, Annexin-V and PI were the same as for THP-1 cells.
Plates were analyzed on a ow cytometer. Cells were classied
according to Annexin-V and PI labeling into viable (non-stained
cells), pre-apoptotic cells (stained with Annexin-V only), cells in
late phases of apoptosis (double stained cells), and necrotic
cells (stained with PI only). Aer this read-out was ended, the
remaining cells were xed in ethanol overnight at 4 C, and
aerwards stained with FxCycle™ PI/RNAse Staining solution
(Molecular Probes, Cat. no. F10797), and analyzed as described
previously.84
Calculation of ED50 concentration
Separately for THP-1 and AsPC-1 cells, the percent of Annexin-V
labeled cells for each investigated concentration of compounds
were summarized and the maximum apoptotic response was
normalized to 100%. The percent of apoptosis read-out for
other concentrations were calculated as a proportion of the
highest response. Such scaled apoptotic outcomes were plotted
against concentrations and ED50 concentration was calculated
using the asymmetric sigmoidal curve ve-parameter logistic
equation (GraphPad Prism 6 soware). The determined ED50
concentrations of both compounds were applied in further
steps of this investigation.
Inhibition of caspase activity
THP-1 and AsPC-1 cells were treated with investigated
compounds at the ED50 concentration for 6 h with or without
pan-caspase inhibitor Z-VAD-fmk (Promega, Cat. no. G7232).
Previously, the proper concentration of Z-VAD-fmk that is non-This journal is © The Royal Society of Chemistry 2015
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View Article Onlinetoxic to cells during 6 h of incubation was determined (10 mM
and 20 mM for THP-1 and AsPC-1 cell lines, respectively). As
controls, non-treated cells, cells treated with Z-VAD-fmk only,
and cells treated with ED50 concentrations only were used. Aer
the incubation period had ended, plates with THP-1 and AsPC-1
treated cells were stained with Annexin-V/PI as described above,
and analyzed on a Guava EasyCyte™ cytometer. The percent of
apoptosis inhibited by Z-VAD-fmk co-treatment was determined
by the formula: apoptosis inhibition, % ¼ [1  (% of apoptosis
in A/% of apoptosis in B)]  100, where A is the sample treated
with both ED50 and Z-VAD-fmk, while B is the corresponding
sample treated with ED50 only.Evaluation of caspase-8 and -9 activities
THP-1 and AsPC1 cells were treated with the investigated
compounds at the ED50 concentration for 6 h. Aerwards the
activity of caspase-8 and -9 were assayed by means of a Guava
Caspase 9 SR and a Caspase 8 FAM kit (EMD Millipore, Cat. no.
4500-0640), following the instructions of the manufacturer. In
acquired data cells were discriminated according to expression
of green uorescence (caspase-8), yellow uorescence (caspase-
9), or red uorescence (7-AAD) as the following: live cells (not
stained with either caspase nor 7-AAD), mid-stage apoptotic
cells (cells stained with either caspase 8 or 9, but negative to 7-
AAD), late stage apoptotic cells (cells stained with either of
caspase 8 or 9 and with 7-AAD), necrotic cells (cells not stained
with either caspase 8 nor 9, but positive for 7-AAD).DNA binding experiments
Calf thymus DNA (lyophilized, highly polymerized, obtained
from Serva, Heidelberg) (CT-DNA) was dissolved in Tris buﬀer
(10 mM Tris–HCL pH 7.9) overnight at 4 C. This stock solution
(2.86 mg mL1) was stored at 4 C and was stable for several
days. A solution of CT-DNA in water gave a ratio of UV absor-
bance at 260 and 280 nm, A260/A280 of 1.89–2.01, indicating that
the DNA was suﬃciently free of protein. The concentration of
DNA (2.86 mg mL1) was determined from the UV absorbance
at 260 nm using the extinction coeﬃcient 3260 ¼ 6600 M1
cm1.85 The complex was dissolved in DMSO in concentrations
of 10 mM. This solution was used as stock solution.
UV-visible measurements. Reaction mixtures (1 mL in 40
mM bicarbonate buﬀer, pH 8.4) consisting of 1, 3 and 6 mL of
the stock solution of 1 and 10 mL of the solution of CT-DNA were
incubated at 37 C for 90 min with occasional vortexing. The
absorbance titrations were performed at a xed concentration
of 1 (30 mM) and gradually increasing the concentration of
double stranded CT-DNA (2.5, 5, 7.5, 10, 12.5, 15, 17.5 and 20
mL). The absorbance at 260 and 344 nm was monitored for each
concentration of DNA. The binding constant Kb was determined
using eqn (5):86
[DNA]  (3a  3f)1 ¼ [DNA]  (3b  3f)1 + Kb1  (3b 
3f)
1 (5)
where 3a, 3f, 3b are absorbance/[1], extinction coeﬃcient of the
free complex and the extinction coeﬃcient of the boundThis journal is © The Royal Society of Chemistry 2015compound, respectively. A plot of [DNA]/(3a  3f) versus [DNA]
gave a slope and intercept equal to 1/(3a  3f) and (1/Kb)(1/(3b 
3f)), respectively. The binding constant Kb was calculated from
the ratio of the slope to the intercept. The percentage of
hyperchromicity or hypochromicity for the CT-DNA/[1] was
determined from: (3a  3f)/3f  100.
Fluorescence measurements. The competitive interactions
of 1 and the uorescence probe (ethidium bromide – EB and
Hoechst 33258 – H) with CT-DNA have been studied by
measuring the change of uorescence intensity of the probe-
DNA solution aer addition of 1. Reaction mixtures contain-
ing 100 mM of CT-DNA (calculated per phosphate) in 1 mL of 40
mM bicarbonate solution (pH 8.4) were pretreated with 1 mL of
the probe solution (25 mM of EB and 28 mM of H at nal
concentrations) for 20 min and the mixture was analyzed by
uorescence measurement. Then gradually increasing concen-
trations of the complex (2, 4, 6, 8 10, 12, 16, 20, 25, 30 and 40 mM
nal concentrations) were successively added and the change in
the uorescence intensity was measured. The slits on the exci-
tation and emission beams were xed at 10 nm. All measure-
ments were performed by excitation at 500 nm in the range 520–
700 nm for EB and by excitation at 350 nm in the range 390–600
nm for H. The control was EB–CT-DNA solution and H–CT-DNA
solution, respectively. The complex did not have uorescence
under the applied conditions. The obtained uorescence
quenching data were analyzed according to the Stern–Volmer
eqn (6):73
I0
I
¼ 1þ Ksv½Q (6)
where I0 and I represent the uorescence intensities of probe–
CT-DNA in the absence and presence of 1, respectively, Ksv is the
quenching constant and [Q] is the concentration ratio of the
complex to DNA ([1]/[CT-DNA]). The Ksv value is calculated from
the ratio of the slope to the intercept from the plot of I0/I versus
[Q].
DNA cleavage experiments
For DNA cleavage experiments the plasmid pUC19 (2686 bp,
purchased from Sigma-Aldrich, USA) was prepared by its
transformation in chemically competent cells Escherichia coli
strain XL1 blue. Amplication of the clone was done according
to the protocol for growing E. coli culture overnight in LB
medium at 37 C (ref. 87) and purication was performed using
a Qiagen Plasmid plus Maxi kit. Finally, DNA was eluted in 10
mM Tris–HCl buﬀer and stored at 20 C. The concentration of
plasmid DNA (512 ng mL1) was determined by measuring the
absorbance of the DNA-containing solution at 260 nm. One
optical unit corresponds to 50 mgmL1 of double stranded DNA.
The cleavage reaction of supercoiled pUC19 DNA by diﬀerent
concentrations of 1 was investigated by incubation of 512 ng of
plasmid in a 20 mL reaction mixture in 40 mM bicarbonate
buﬀer (pH 8.4) at 37 C, for 90 min. The reaction mixtures were
vortexed from time to time. The reaction was terminated by
short centrifugation at an RCF of 6708  g and addition of 5 mL
of loading buﬀer [0.25% bromophenol blue, 0.25% xylene cya-
nol FF and 30% glycerol in TAE buﬀer, pH 8.24 (40 mM Tris–RSC Adv., 2015, 5, 95191–95211 | 95207
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View Article Onlineacetate, 1 mM EDTA)]. The samples were subjected to electro-
phoresis on 1% agarose gel (Amersham Pharmacia-Biotech, Inc)
prepared in TAE buﬀer pH 8.24. The electrophoresis was per-
formed at a constant voltage (80 V) until bromophenol blue had
passed through 75% of the gel. Aer electrophoresis, the gel was
stained for 30 min by soaking it in an aqueous ethidium
bromide solution (0.5 mg mL1).HSA binding experiments
Fatty acid free HSA (<0.007% fatty acids, Mw ¼ 66 478 Da) was
purchased from Sigma, as well as potassium dihydrogen
phosphate, disodium hydrogen phosphate, sodium chloride
and potassium chloride used for 1 PBS preparation. A stock
solution of HSA (c ¼ 2.78  103 M) was prepared by dissolving
an accurately weighed mass of commercially available lyophi-
lized HSA in freshly prepared 1 PBS (pH ¼ 7.35), and kept in
a freezer in 100 mL portions. A stock solution of 1 (c ¼ 6.36 
104 M) was prepared by dissolving an appropriate amount of
substance in DMSO. For HSA–1 interaction studies, the HSA
solution was freshly prepared from the stock by dilution with
PBS buﬀer (HSA concentration was kept constant, c ¼ 5  107
M), and titrated with small volume increments of 1 stock
solution (to avoid large sample dilution). The complex was
added in 0.7, 1.4, 2.8, 4.2, 6.3, 8.4 and 10.5 molar equivalents.
Aer each aliquot addition, the system was stirred and le to
equilibrate for 15 min before UV-Vis absorption and uores-
cence emission spectra recording. Aer the last equivalent, the
total DMSO did not exceed 2% in volume. It was previously
shown that addition of 15% of DMSO did not induce structural
changes in bovine serum albumin, a protein structurally similar
to HSA.88 Therefore, it is unlikely that the conformation of HSA
was changed with the level of DMSO used in this study. Milli-
pore water was used for all aqueous solutions. All UV-Vis spectra
were recorded against the corresponding blank (PBS) in the
250–450 nm wavelength range at room temperature.
Before recording the uorescence spectrum, diluted HSA
solution was ultraltrated using lters with 0.23 mm pore size.
The excitation wavelength was 280 nm, with 5 nm slits; emis-
sion spectra were recorded in the 300–450 nm wavelength
range, with 5 nm slits, and 0.1 s integration time. The back-
ground PBS signal was subtracted from each spectrum. In order
to remove the instrumental inner lter eﬀect, the absorbances
were measured at the excitation (280 nm) and emission (340
nm) wavelengths, and uorescence intensities corrected
according to the Lakowicz eqn (7):73
Fcorr ¼ Fobs  10
AexþAem
2 (7)
where Fcorr and Fobs are corrected and observed uorescence
intensities, and Aex and Aem are absorbances at the excitation
and emission wavelengths, respectively.
Fluorescence quenching data were processed using the
Stern–Volmer eqn (8):73
F0
F
¼ 1þ Ksv½Q ¼ 1þ Kqs0½Q (8)95208 | RSC Adv., 2015, 5, 95191–95211where F0 and F represent HSA uorescence intensities in the
absence (F0) and in the presence of the quencher (F), Ksv and Kq
are the Stern–Volmer quenching constant and the quenching
rate constant of protein, respectively, s0 is the average uores-
cence lifetime (7.09 ns for HSA),74 and [Q] is the concentration
of the quencher (1).
The quenching process was additionally analyzed using
a modied Stern–Volmer eqn (9):73
F0
DF
¼ 1
faKa
1
½Q þ
1
fa
(9)
where DF is the diﬀerence in uorescence intensity of HSA in
the absence (F0) and in the presence of the quencher at
concentration [Q]. Ka represents the eﬀective quenching
constant for the accessible uorophores, and fa is the fraction of
accessible uorophore.
Thermodynamic parameters of binding, the enthalpy (DH)
and entropy change (DS), during the binding of 1 to HSA were
determined by measuring the binding constants at several
temperatures, and following the Van’t Hoﬀ eqn (10):
ln Ka ¼  DH
RT
þ DS
R
(10)
where R is the universal gas constant, T is the temperature (in
K), and Ka is the eﬀective quenching constant at the corre-
sponding temperature.
The distance between donor and acceptor, r, was calculated
using eqn (11) for energy transfer eﬃciency, E:73
E ¼ 1 F
F0
¼ R0
6
R0
6 þ r6 (11)
where R0 is called the Fo¨rster’s distance, and represents the
distance at which energy transfer is 50% eﬃcient. R0 is calcu-
lated according to eqn (12):
R0
6 ¼ 8.79  1025k2n4fJ (12)
where k2 stands for the spatial orientation factor of the dipole, n
is a refractive index of the medium, f is the donor uorescence
quantum yield, and J is the overlap integral of the donor
emission and the acceptor absorption spectra. The overlap
integral, J, can be calculated according to eqn (13):
J ¼
ÐN
0
FðlÞ3ðlÞl4dl
ÐN
0
FðlÞdl (13)
where F(l) is uorescence intensity (corrected for inner lter
eﬀect) of the donor in the wavelength of interest (in this case
300–450 nm) and 3 is specic molar absorptivity of acceptor at
certain wavelength. In the present study, k2 ¼ 2/3 (for randomly
oriented dipoles), n ¼ 1.336, and f ¼ 0.118 were used.89Computational details
Theoretical IR spectrum of 1. The geometry of 1 was opti-
mized and vibrational frequencies were calculated at the
B97D90/TZVP91,92 level of theory in Gaussian 09, Revision D.01
soware.93 The IR spectrum was visualized using GaussView 5,94This journal is © The Royal Society of Chemistry 2015
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View Article Onlineand the corresponding data were exported as a text le in the
range 0–4000 cm1 with step size 1 cm1.
Molecular docking studies. Two randomly chosen X-ray
crystal structures of dodecamer d(CGCGAATTCGCG)2, PDB ID:
3U2N95 and PDB ID: 4U8A,96 and three HSA structures, PDB IDs:
1BJ5,97 2BXD98 and 4L9Q,99 were obtained from the Protein Data
Bank (http://www.rcsb.org/pdb). The active sites were identied
according to positions of crystallized ligands in the PDB struc-
tures. Ligands were removed, as well as water and ions and
structures were prepared for docking using Autodock Tools
1.5.6.100,101 Docking was carried in Autodock Vina 1.1.2.102 The
grid box size was set to 24  24  24 A˚ and exhaustiveness to
250. All calculations were carried on PARADOX computer
cluster (Scientic Computing Laboratory of the Institute of
Physics, Belgrade, Serbia). Hqasesc and 1 were prepared using
X-ray determined coordinates, with Gasteiger charge correction
done with Chimera program,103 as no charges were assigned for
selenium atoms.
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